Hi Folks,
Cosmos Health Inc. (Nasdaq: COSM) is showing another bullish signal worth paying attention to.
According to Investing.com's technical analysis, COSM's technical indicators are signaling a "Strong Buy" rating.
That's an encouraging technical signal, particularly alongside the company's recent 92% surge in U.S. subscriptions and accelerating revenue growth.
Technical ratings can change quickly, but this adds another reason to keep COSM firmly on your radar.
Cosmos Health Inc. (Nasdaq: COSM) just announced breaking news this morning, reporting a 92% surge in active U.S. subscriptions in just 14 days.
Subscriptions climbed from 6,287 on October 14 to 12,050 on October 28.
Nearly 6,000 additional subscriptions in just two weeks.
That's impressive growth for a business Cosmos launched only a few months ago.
For a healthcare company that only launched its U.S. subscription model in July, that's a substantial increase in a very short period.
Monthly Subscription Value Jumps 94%
And the growth doesn't stop there.
Cosmos reported that monthly subscription value surged 94% in just two weeks, climbing from $919,945 to nearly $1.8M.
That represents potential monthly billings at standard renewal pricing, not revenue already collected.
But as subscribers continue renewing, Cosmos has the potential to build a substantial recurring revenue stream.
Online Orders Surge 90%
Cosmos also reported that online checkout orders jumped 90% to 20,677 in just 14 days.
Meanwhile, active subscriptions increased another 35% in the final nine days of that period.
These are impressive early growth numbers for a company building a new recurring revenue business.
International Expansion Is Underway
And Cosmos isn't stopping with the U.S.
Management says its subscription model is already live in Australia, New Zealand and the broader Oceania region.
If that expansion gains traction, recurring subscriptions could become a much bigger contributor to the company's revenue.
Wall Street Sees Substantial Upside
Here's something else worth keeping in mind.
Even before today's 92% subscription growth announcement, two research firms had issued bullish price targets on COSM.
Noble Capital Markets: $1.40 Price Target
Noble initiated coverage with an outperform rating and a $1.40 price target, representing approximately 418% implied upside from the share price referenced in its research.
Zacks Small-Cap Research: $4.50 Price Target
Zacks reiterated coverage with a $4.50 price target, representing approximately 1,566% implied upside from its referenced share price.
Analyst targets aren't guarantees, but those are substantial projections.
Now consider today's announcement.
92% subscription growth. A 94% jump in monthly subscription value. Online orders climbing 90%. And international expansion underway.
That's a combination of catalysts I believe deserves serious attention, even as customer retention and profitability remain important to watch.
I want COSM at the TOP of your watchlist.
Keep it pulled up and follow the next developments closely.
To your success,
Michael Reece
© 2026 FinancialDrivenResearch.com. All rights reserved. You are receiving this email as part of your subscription to FinancialDrivenResearch.com. This publication is provided for informational purposes only and should not be considered personalized financial or investment advice. Financial Driven Research is a financial publisher, not a registered investment adviser or broker-dealer. Nothing in this publication constitutes an offer to sell or a solicitation of an offer to buy any security. Readers should conduct their own research and consult a qualified financial professional before making investment decisions. This communication is sponsored. Pursuant to an agreement between Financial Driven Research and STM LLC, Financial Driven Research has been hired to publish and disseminate information about COSM for one day of coverage on October 29, 2026. Under this agreement, STM LLC has paid Financial Driven Research ten thousand USD. Financial Driven Research does not own, hold, or maintain any position in the securities of COSM and does not trade securities featured in its publications.